All In Biotech

Drug Trial Radar · NCT07880392

Efficacy and Safety of DNN.63.18.040 for the Treatment of Moderate to Severe Pain

A Randomized Clinical Trial to Evaluate the Safety and Efficacy of DNN.63.18.040 for the Treatment of Moderate to Severe Pain

Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 370 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

370

Planned (sponsor's estimate)

Start

Oct 19, 2026

Primary completion

Mar 2027

Study completion Apr 2027

Sponsor

Sponsor type
Industry
First posted
Oct 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 49 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates the safety and efficacy of DNN.63.18.040 compared with Tramal® for the treatment of moderate to severe pain.

Conditions

  • Acute Pain

Interventions

  • Product DNN.63.18.040Drug

    One capsule four times daily for 3 days

  • Tramal®Drug

    One capsule four times daily for 3 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total Pain Relief Score (TOTPAR6)Time frame: 6 hours after first dose

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.